RUNX1 Familial Platelet DisorderSymptoms, Doctors, Treatments, Advances & More
RUNX1 Familial Platelet Disorder Overview
Learn About RUNX1 Familial Platelet Disorder
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Lucy Godley is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. She has been practicing medicine for over 29 years. Dr. Godley is rated as an Elite provider by MediFind in the treatment of RUNX1 Familial Platelet Disorder. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses RUNX1 Familial Platelet Disorder, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Godley is board certified in American Board Of Internal Medicine - Hematology (Certified).
Tim Ripperger practices practicing medicine in Hannover, Germany. Mr. Ripperger is rated as an Elite expert by MediFind in the treatment of RUNX1 Familial Platelet Disorder. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses RUNX1 Familial Platelet Disorder, Turcot Syndrome, Li-Fraumeni Syndrome, Leukemia, and Colonoscopy.
Torsten Haferlach practices practicing medicine in Munich, Germany. Mr. Haferlach is rated as an Elite expert by MediFind in the treatment of RUNX1 Familial Platelet Disorder. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), RUNX1 Familial Platelet Disorder, and Bone Marrow Transplant.
Background: Runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations of this gene may bleed or bruise easily; they are also at higher risk of getting cancers of the blood, bone marrow, and lymph nodes.
Summary: To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.